uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses
The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma. Between January 2002 and March 2011, 2217 patients with...
Gespeichert in:
| Veröffentlicht in: | Cancer cytopathology 2013-07, Vol.121 (7), p.392-397 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 397 |
|---|---|
| container_issue | 7 |
| container_start_page | 392 |
| container_title | Cancer cytopathology |
| container_volume | 121 |
| creator | COMPLOJ, Evi MIAN, Christine AMBROSINI-SPALTRO, Andrea DECHET, Christopher PALERMO, Salvatore TRENTI, Emanuela LODDE, Michele HORNINGER, Wolfgang PYCHA, Armin |
| description | The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.
Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.
Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).
On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-397. © 2013 American Cancer Society. |
| doi_str_mv | 10.1002/cncy.21287 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1400397393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1400397393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1216-3a1f2d8f8e35ee621f474500f65a9a9464b0eb473aeb271135409b9357aebf723</originalsourceid><addsrcrecordid>eNpFkEtLw0AUhQdRbK1u_AEyG0GUtPNKJnFX4qtQcGPBXbiZzmgkmamZZJF_79TWChfO5fBxFh9Cl5RMKSFspqwapoyyVB6hMc24iJKEp8eHn72P0Jn3X4TQVDJ6ikaMiywmSTJG0OdDdzdbNE1vXXgx2DUO6Wr3MeDK4u5T4wfdadVVzmJn8Kp1oasrqHEOraqsa-Aezy1ebdbQaRwoKRgLDdSD1_4cnRiovb7Y5wStnh7f8pdo-fq8yOfLSFFGk4gDNWydmlTzWOuEUSOkiAkxSQwZZCIRJdGlkBx0ySSlPBYkKzMey1AYyfgE3ex2N6377rXviqbyStc1WO16X1BBCM8kz3hAb3eoap33rTbFpq0aaIeCkmKrtNgqLX6VBvhqv9uXjV4f0D-HAbjeA-AV1KYFqyr_z8mYb4__ACwyfN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400397393</pqid></control><display><type>article</type><title>uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>COMPLOJ, Evi ; MIAN, Christine ; AMBROSINI-SPALTRO, Andrea ; DECHET, Christopher ; PALERMO, Salvatore ; TRENTI, Emanuela ; LODDE, Michele ; HORNINGER, Wolfgang ; PYCHA, Armin</creator><creatorcontrib>COMPLOJ, Evi ; MIAN, Christine ; AMBROSINI-SPALTRO, Andrea ; DECHET, Christopher ; PALERMO, Salvatore ; TRENTI, Emanuela ; LODDE, Michele ; HORNINGER, Wolfgang ; PYCHA, Armin</creatorcontrib><description>The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.
Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.
Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).
On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-397. © 2013 American Cancer Society.</description><identifier>ISSN: 1934-662X</identifier><identifier>EISSN: 1934-6638</identifier><identifier>DOI: 10.1002/cncy.21287</identifier><identifier>PMID: 23495066</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Biological and medical sciences ; Cystoscopy ; Cytodiagnosis ; Female ; Follow-Up Studies ; Humans ; Immunoenzyme Techniques ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Grading ; Prognosis ; Tumors ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - urine ; Urine - cytology ; Young Adult</subject><ispartof>Cancer cytopathology, 2013-07, Vol.121 (7), p.392-397</ispartof><rights>2014 INIST-CNRS</rights><rights>2013 American Cancer Society.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1216-3a1f2d8f8e35ee621f474500f65a9a9464b0eb473aeb271135409b9357aebf723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27537537$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23495066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>COMPLOJ, Evi</creatorcontrib><creatorcontrib>MIAN, Christine</creatorcontrib><creatorcontrib>AMBROSINI-SPALTRO, Andrea</creatorcontrib><creatorcontrib>DECHET, Christopher</creatorcontrib><creatorcontrib>PALERMO, Salvatore</creatorcontrib><creatorcontrib>TRENTI, Emanuela</creatorcontrib><creatorcontrib>LODDE, Michele</creatorcontrib><creatorcontrib>HORNINGER, Wolfgang</creatorcontrib><creatorcontrib>PYCHA, Armin</creatorcontrib><title>uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses</title><title>Cancer cytopathology</title><addtitle>Cancer Cytopathol</addtitle><description>The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.
Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.
Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).
On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-397. © 2013 American Cancer Society.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal</subject><subject>Biological and medical sciences</subject><subject>Cystoscopy</subject><subject>Cytodiagnosis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Grading</subject><subject>Prognosis</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urine - cytology</subject><subject>Young Adult</subject><issn>1934-662X</issn><issn>1934-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLw0AUhQdRbK1u_AEyG0GUtPNKJnFX4qtQcGPBXbiZzmgkmamZZJF_79TWChfO5fBxFh9Cl5RMKSFspqwapoyyVB6hMc24iJKEp8eHn72P0Jn3X4TQVDJ6ikaMiywmSTJG0OdDdzdbNE1vXXgx2DUO6Wr3MeDK4u5T4wfdadVVzmJn8Kp1oasrqHEOraqsa-Aezy1ebdbQaRwoKRgLDdSD1_4cnRiovb7Y5wStnh7f8pdo-fq8yOfLSFFGk4gDNWydmlTzWOuEUSOkiAkxSQwZZCIRJdGlkBx0ySSlPBYkKzMey1AYyfgE3ex2N6377rXviqbyStc1WO16X1BBCM8kz3hAb3eoap33rTbFpq0aaIeCkmKrtNgqLX6VBvhqv9uXjV4f0D-HAbjeA-AV1KYFqyr_z8mYb4__ACwyfN4</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>COMPLOJ, Evi</creator><creator>MIAN, Christine</creator><creator>AMBROSINI-SPALTRO, Andrea</creator><creator>DECHET, Christopher</creator><creator>PALERMO, Salvatore</creator><creator>TRENTI, Emanuela</creator><creator>LODDE, Michele</creator><creator>HORNINGER, Wolfgang</creator><creator>PYCHA, Armin</creator><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201307</creationdate><title>uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses</title><author>COMPLOJ, Evi ; MIAN, Christine ; AMBROSINI-SPALTRO, Andrea ; DECHET, Christopher ; PALERMO, Salvatore ; TRENTI, Emanuela ; LODDE, Michele ; HORNINGER, Wolfgang ; PYCHA, Armin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1216-3a1f2d8f8e35ee621f474500f65a9a9464b0eb473aeb271135409b9357aebf723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal</topic><topic>Biological and medical sciences</topic><topic>Cystoscopy</topic><topic>Cytodiagnosis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Grading</topic><topic>Prognosis</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urine - cytology</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>COMPLOJ, Evi</creatorcontrib><creatorcontrib>MIAN, Christine</creatorcontrib><creatorcontrib>AMBROSINI-SPALTRO, Andrea</creatorcontrib><creatorcontrib>DECHET, Christopher</creatorcontrib><creatorcontrib>PALERMO, Salvatore</creatorcontrib><creatorcontrib>TRENTI, Emanuela</creatorcontrib><creatorcontrib>LODDE, Michele</creatorcontrib><creatorcontrib>HORNINGER, Wolfgang</creatorcontrib><creatorcontrib>PYCHA, Armin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer cytopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COMPLOJ, Evi</au><au>MIAN, Christine</au><au>AMBROSINI-SPALTRO, Andrea</au><au>DECHET, Christopher</au><au>PALERMO, Salvatore</au><au>TRENTI, Emanuela</au><au>LODDE, Michele</au><au>HORNINGER, Wolfgang</au><au>PYCHA, Armin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses</atitle><jtitle>Cancer cytopathology</jtitle><addtitle>Cancer Cytopathol</addtitle><date>2013-07</date><risdate>2013</risdate><volume>121</volume><issue>7</issue><spage>392</spage><epage>397</epage><pages>392-397</pages><issn>1934-662X</issn><eissn>1934-6638</eissn><abstract>The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.
Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.
Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).
On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-397. © 2013 American Cancer Society.</abstract><cop>Hoboken, NJ</cop><pub>Wiley</pub><pmid>23495066</pmid><doi>10.1002/cncy.21287</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1934-662X |
| ispartof | Cancer cytopathology, 2013-07, Vol.121 (7), p.392-397 |
| issn | 1934-662X 1934-6638 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1400397393 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal Biological and medical sciences Cystoscopy Cytodiagnosis Female Follow-Up Studies Humans Immunoenzyme Techniques Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Grading Prognosis Tumors Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - urine Urine - cytology Young Adult |
| title | uCyt+/ImmunoCyt and Cytology in the Detection of Urothelial Carcinoma: An Update on 7422 Analyses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T04%3A36%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=uCyt+/ImmunoCyt%20and%20Cytology%20in%20the%20Detection%20of%20Urothelial%20Carcinoma:%20An%20Update%20on%207422%20Analyses&rft.jtitle=Cancer%20cytopathology&rft.au=COMPLOJ,%20Evi&rft.date=2013-07&rft.volume=121&rft.issue=7&rft.spage=392&rft.epage=397&rft.pages=392-397&rft.issn=1934-662X&rft.eissn=1934-6638&rft_id=info:doi/10.1002/cncy.21287&rft_dat=%3Cproquest_cross%3E1400397393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400397393&rft_id=info:pmid/23495066&rfr_iscdi=true |